AtaiBeckley secured co-development and royalty offers before $2.8 B Lilly acquisition

AtaiBeckley, a psychedelic biotech, received co-development and royalty proposals prior to finalizing a $2.8 B acquisition by Eli Lilly.

Details were disclosed in an SEC filing that outlined the sequence of offers and negotiations, showing strong industry interest in the company's pipeline.

The deal is described as the largest psychedelic biotech buyout to date, highlighting growing investment in the sector.